Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial

Category Primary study
JournalJournal of Clinical Oncology
Year 2020
This article has no abstract
Epistemonikos ID: aabe558366d9c8bffcf0ddd294f46f8342b38ec9
First added on: Feb 13, 2025